Gap May Exist for Therapies for Age-related Diseases - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Gap May Exist for Therapies for Age-related Diseases

Source: Applied Clinical Trials

The elderly is the fastest-growing segment of the global population, but only a few of their treatments have been clinically tested in age-appropriate patients, and many therapies are still not available in suitable formulations and dosages, according to a report by GBI Research.

Many older people suffer from comorbid conditions and one in three takes at least five drugs or more on a daily basis, which significantly increases the risk of adverse drug events and hospitalization, with up to one third of elderly emergency admissions being drug-related, note the report (Geriatric Medicine Development - Carving Out New Opportunities to Treat Age-Related Diseases).

Pre-marketing drug trials often exclude geriatric patients and approved doses are not likely to be appropriate for the elderly, making off-label prescriptions relatively common for older patients. Antipsychotic medications, for example, are regularly prescribed off-label in up to 80% of care-home patients, to manage delirium, agitation and psychosis resulting from Alzheimer’s disease and schizophrenia, and these drugs have been associated with an increased risk of diabetes, cerebrovascular events and death, according to the authors.

The development of age-appropriate formulations and doses could allow for smarter prescriptions of approved drugs, such as anti-coagulants, anti-diabetic agents, antipsychotics and analgesics in older people, they note. Additionally, opportunities exist for companies to develop medicines for age-related diseases, including cognitive impairment, sarcopenia and neurodegenerative diseases.

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here